All stock lists
Kardigan, Inc. (NASDAQ:KARD)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$13.00-$1.12 (-7.93%)
Market cap
$1.16B
Insider Score
Health Score
Analyst consensus
Listed since
Jun 18, 2026
Website
Insider Score
––Not scored
KARD Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
KARD analyst forecast
KARD analyst consensus
Moderate Buy1 ratings
Buy 1 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
KARD 12-month price target
$25.00+88.0% upsideaverage of 1 firm
$25.00High
$25.00Low
Best analysts covering KARD
No firm covering KARD has a call old enough to have finished a 1Y holding period yet.
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
KARD analyst ratings
Filters
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| UBS | — | $25.00 | +70.4% | Price target | 2026-10-12 | |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-08-25 |
KARD earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-05-26 | $0.00 | -$3.86 | $0 | $0 |
| 2026-08-11 | -$0.68 | -$2.88 | $0 | $0 |
| 2026-11-12 | -$0.78 | -$0.64 | $250K | $0 |
| 2027-02-11Upcoming | -$0.72 | — | $333K | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.